Trials / Active Not Recruiting
Active Not RecruitingNCT07128615
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AZD4117 | Intramuscular (IM) injection |
| BIOLOGICAL | AZD5315 | IM injection |
| OTHER | Placebo | IM injection |
Timeline
- Start date
- 2025-09-04
- Primary completion
- 2026-01-28
- Completion
- 2026-12-29
- First posted
- 2025-08-19
- Last updated
- 2026-03-23
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07128615. Inclusion in this directory is not an endorsement.